MAIA Biotechnology, Inc. announced on March 2, 2026, that it has entered into an underwriting agreement to sell 20 million shares of common stock at $1.50 each, expecting to raise approximately $30 million. The offering's closing occurred on March 4, 2026, and will fund clinical trials and general corporate purposes.